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Abstract
Background: Hyperoxia plays an important role in the genesis of lung injury in preterm infants. Although alveolar
type II cells are the main target of hyperoxic lung injury, the exact mechanisms whereby hyperoxia on fetal
alveolar type II cells contributes to the genesis of lung injury are not fully defined, and there have been no specific
measures for protection of fetal alveolar type II cells.
Objective: The aim of this study was to investigate (a) cell death response and inflammatory response in fetal
alveolar type II cells in the transitional period from canalicular to saccular stages during 65%-hyperoxia and (b)
whether the injurious stimulus is promoted by creating an imbalance between pro- and anti-inflammatory
cytokines and (c) whether treatment with an anti-inflammatory cytokine may be effective for protection of fetal
alveolar type II cells from injury secondary to 65%-hyperoxia.
Methods: Fetal alveolar type II cells were isolated on embryonic day 19 and exposed to 65%-oxygen for 24 h and
36 h. Cells in room air were used as controls. Cellular necrosis was assessed by lactate dehydrogenase-release and
flow cytometry, and apoptosis was analyzed by TUNEL assay and flow cytometry, and cell proliferation was studied
by BrdU incorporation. Release of cytokines including VEGF was analyzed by ELISA, and their gene expressions
were investigated by qRT-PCR.
Results: 65%-hyperoxia increased cellular necrosis, whereas it decreased cell proliferation in a time-dependent
manner compared to controls. 65%-hyperoxia stimulated IL-8-release in a time-dependent fashion, whereas the
anti-inflammatory cytokine, IL-10, showed an opposite response. 65%-hyperoxia induced a significant decrease of
VEGF-release compared to controls, and similar findings were observed on IL-8/IL-10/VEGF genes expression.
Preincubation of recombinant IL-10 prior to 65%-hyperoxia decreased cellular necrosis and IL-8-release, and
increased VEGF-release and cell proliferation significantly compared to hyperoxic cells without IL-10.
Conclusions: The present study provides an experimental evidence that IL-10 may play a potential role in
protection of fetal alveolar type II cells from injury induced by 65%-hyperoxia.
Introduction
Administration of high concentrations of oxygen is a
therapeutic mainstay for premature infants with respira-
tory distress syndrome since birth. However, prolonged
exposure to hyperoxia, by generating excess reactive
oxygen species, can generate lung injury [1-5] that leads
to bronchopulmonary dysplasia (BPD) in preterm
infants [6]. BPD has a multifactorial etiology, but one of
the most immediate causes of BPD is lung injury
imposed by hyperoxia [7], of which major biological
effects include cell death and inflammatory response [8].
Alveolar type II cells are key components of alveolar
structure. They participate in innate immune response
by secreting chemokines and cytokines and are responsi-
ble for fluid homeostasis in alveolar lumen and restora-
tion of normal alveolar epithelium after acute lung
injury [9]. Hence, alveolar type II cells are the critical
target of hyperoxia-mediated lung injury, and the rate of
alveolar type II cell death is a critical factor determining
the capacity of the epithelium to repair damage and
should be related to the development of BPD [10]. Pre-
vious in vitro study of adult alveolar type II cells has
demonstrated that 95%-hyperoxia increased lactate
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moxic cells [11].
Hyperoxia-induced lung injury is characterized by
lung edema, extensive inflammatory response and
destruction of the alveolar-capillary barrier [5,12-14].
These effects are orchestrated by cytokines which
amplify inflammatory cell influx into the lungs [15].
Increased level of pro-inflammatory cytokines and che-
mokines such as IL-8, TNFa, IL-1b, IL-6, IL-16, macro-
phage inflammatory protein (MIP-1) and monocyte
chemoattractant protein (MCP-1) have been demon-
strated in airway secretions of preterm infants with BPD
[16]. IL-8, which is released by alveolar macrophages,
fibroblasts, type II cells and endothelial cells, is consid-
ered as the most important chemotactic factor during
the acute phase of lung inflammation [17,18]. In con-
trast, IL-10 is an anti-inflammatory cytokine that regu-
lates the production of pro-inflammatory cytokines [9].
Recently, there have been growing concerns regarding
the inability to regulate inflammation as a factor in
development of BPD in preterm infants [19]. These con-
cerns are based on previous evidence showing reduced
response of IL-10 in bronchoalveolar lavage fluids of
preterm infants with BPD [20,21].
In recent years, the features of BPD have changed.
The lesions of altered patterns of atelectasis, overinfla-
tion and extensive fibroproliferation in “old”“ BPD” have
been replaced in “new”“ BPD” with marked alveolar and
capillary hypoplasia [22], resulting in developmental
arrest of the lungs [23]. It is clear that coordination of
distal lung vasculogenesis and alveolarization is essential
for lung development [24], therefore, they are strongly
considered to be under paracrine regulation, while
VEGF expression reduced by hyperoxia is presumed to
be mainly due to suppressed expression by alveolar type
II cells [25].
We previously reported that recombinant IL-10 (rIL-
10) administration is effective in attenuating type II cell
injury induced by high amplitude stretch by reducing
apoptosis and IL-8-release in fetal alveolar type II cells
(FATIICs) [26]. Herein, we investigate cell death and
inflammatory response in FATIICs exposed to sublethal
hyperoxia, and further evaluate the effect of IL-10 admi-
nistered to these exposed FATIICs, using an in vitro
model in which rat FATIICs are isolated on embryonic
day 19 (E19) of gestation (transition from canalicular to
saccular stages of lung development).
Methods
Cell isolation, hyperoxia protocol and treatment
procedure
Fetal rat lungs were obtained from time-pregnant Spra-
gue-Dawley rats (Daehan Biolink, Eumsung, South
Korea) on E19 (term = 22 days). Animal care and
experimental procedures were performed in accordance
with the Guidelines for Animal Experimentation of
Kangwon National University School of Medicine with
approval of the Institutional Animal Care. Extracted tis-
sues were finely minced and digested with 0.5 mg/ml
collagenase type I and 0.5 mg/ml collagenase type IA
(Sigma Chemical Co., St. Louis, MO, USA) with vigor-
ous pipetting for 15 min at 37°C. After collagenase
digestion, cell suspensions were sequentially filtered
through 100-, 30-, and 20-μm nylon meshes using
screen cups (Sigma Chemical Co., St. Louis, MO, USA).
The filtrate from 20-μm nylon mesh, containing mostly
fibroblasts, was discarded. Clumped non-filtered cells
from the 30- and 20-μm nylon meshes were collected
after several washes with DMEM (Dulbecco’sM o d i f i e d
Eagle Medium) to facilitate filtration of non-epithelial
cells. Further type II cell purification was achieved by
incubating cells in 75-cm
2 flasks for 30 min. Non-adher-
ent cells were collected and cultured overnight in 75-
cm
2 flasks containing serum-free DMEM. Purity of the
type II cell fraction was determined to be 90 ± 5% by
microscopic analysis of epithelial cell morphology and
immune-blotting for cytokeratin/surfactant protein-C
and vimentin as markers of epithelial cells and fibro-
blasts respectively [27]. After overnight culture, type II
epithelial cells were harvested with 0.25%(wt/vol) trypsin
in 0.4 mM EDTA and plated at a density of 10 × 10
5
cells/well on 6-well plates precoated with laminin [10
μg/ml]. Plates containing adherent cells were maintained
for an additional 24 h in serum-free DMEM and then
incubated in a culture chamber with ProOx Oxygen
Controller with Low profile right angle sensor (Bio-
Spherix, Redfiled, NY, USA). 65%-hyperoxia was applied
for 24 h and 36 h, and cells grown in room air (5%
CO2) were treated in an identical manner and served as
controls. For the study of preincubation of rIL-10, the
c e l l sc u l t u r e di na ni d e n t i c al manner were treated with
rIL-10, at a concentration of 300 ng/ml for 1 h before
hyperoxia exposure. The concentration of rIL-10, 300
ng/ml, was chosen based on our previous study showing
that 300 ng/ml of rIL-10 affected greatly on reducing
apoptosis and IL-8-release in FATIICs exposed to
mechanical stretching [26]. And for the study to inden-
tify the characteristics of the dual positive cells (Annexin
V-positive and propidium iodide-positive) with FACs-
can, the cells cultured in an identical manner were incu-
bated in 65%-hyperoxia and room air (5% CO2)a t
intervals of 6-12 h for 48 h.
Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) activity was measured
using a CytoTox 96
® non-radioactive cytotoxicity assay
(Promega, Madison, WI, USA), according to the manu-
facturer’s protocol. This assay measures LDH-release
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was measured as % cytotoxicity [experimental LDH-
release (OD490) per maximal LDH-release (OD490)].
LDH-releases were compared to the difference between
the LDH-release in control samples. LDH was analyzed
with a coupled enzymatic assay that results in the con-
version of a tetrazolium salt into a red formazan pro-
duct. The amount of color formed is proportional to the
number of lysated cells. Absorbance at wavelength 490
nm was collected using a standard 96-well plate reader
(Ultraspec 2100 pro, Amersham Pharmacia Biotech,
Amersham, UK). LDH was quantified by dividing
experimental LDH-release by maximal LDH-release (cal-
culated after complete lysis of monolayers containing
similar numbers of cells to the samples). This value was
used as a common denominator for all samples tested.
FACS analysis
FACS analysis was performed using an Annexin V-FITC
apoptosis kit (BD Pharmingen, Franklin Lakes, NJ,
USA), and analyzed by a flow cytometer (Becton Dickin-
son, Franklin Lakes, NJ, USA). FATIICs incubated at
room air and 65%-hyperoxia in the presence and
absence of 300 ng/ml of rIL-10 were washed, trypsinized
and collected into each tube. Cells in trypsin were cen-
trifuged at 1300 rpm for 3 min at 4°C, and resuspended
in 1X Binding Buffer, and then 5 μl of FITC Annexin V
(AV) and 5 μl of propidium iodide (PI) were added.
After vortexing gently, the cells were incubated for 15
min at room air (25°C) in the dark. 400 ul of 1X binding
buffer was added, and the cells were analyzed by flow
cytometry.
TUNEL assay
Detection and quantification of apoptotic cells were per-
formed using terminal deoxynucleotidyl transferase-
mediated dUTP-FITC nick-end labeling (TUNEL) by a
fluorescein lable apoptosis detection system (Promega,
Madison, WI, USA). Under experimental conditions,
E19 monolayers were fixed in freshly prepared 4% paraf-
ormaldehyde in PBS for 25 min at 4°C, and permeabi-
lized by immersion in 2.0% Triton X-100 in PBS.
Positive controls were cells treated with Dnase I to
induce DNA fragmentation. Monolayers were incubated
at 37°C for 60 min in equilibration buffer, 2-deoxynu-
cleotide 5’-triphosphate, and terminal deoxynucleotidyl-
transferase (TdT) enzyme as per manufacturer’s
protocol. A further control was prepared by omitting
the TdT enzyme. Samples were washed in PBS,
mounted with Vectashield mounting medium with PI
(Vector Laboratories, Burlington, CA, USA), and ana-
lyzed by fluorescence microscopy. For quantification of
apoptotic cells, 50 high-power fields per sample were
analyzed. Areas from each membrane quadrant were
randomly chosen and photographed. Cells containing
green fluorescence and either nuclear condensation or
chromatin fragmentation (without nuclear morphologi-
cal changes) were identified as apoptotic cells. Results
were expressed as TUNEL positive index (number of
TUNEL positive cells per number of total cells).
Western blot of caspase-3
E19 type II cells were exposed to 65%-hyperoxia for 24
h and 36 h, and cells in room air were used as controls.
Monolayers were lysed with RIPA buffer containing pro-
tease inhibitors [28]. Lysates were centrifuged and total
contents were determined by the bicinchoninic acid
method. Equal amounts of protein lysate samples (20
μg) were fractionated by NU-PAGE Bis-Tris (4-12%) gel
electrophoresis (Novex, SanDiego, CA, USA) and trans-
ferred to polyvinylidene difluoride membranes. Blots
were hybridized with polyclonal antibody against the 11/
17/20-kDa cleaved caspase-3 and 32-kDa full-length
procaspase-3 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) to detect activated caspase-3 and full-length
caspase-3. Secondary antibody was conjugated with
horseradish peroxidase, and blots were developed by
exposing them to X-ray film. Membranes were then
stripped and reprobed with actin antibody, and pro-
cessed as described previously in this manuscript.
Type II cell proliferation assay
Measurements of cell proliferation were analyzed by
DNA incorporation of the thymidine analog 5-bromo’-
deoxyuridine (BrdU) as described by the manufacturer
(Boehringer Mannheim, Germany). Briefly, cultures
(>90% confluence) were maintained in hyperoxic condi-
tions or not, and immediately before each experiment,
fresh medium containing 10 uM of BrdU labeling
reagent was added to each well. At the end of each
experiment, monolayers were washed with PBS and
then fixed in 100% methanol for 20 min at -20°C. Cells
were then washed and incubated with anti-BrdU anti-
body (negative controls were incubated with PBS) fol-
lowed by incubation in fluorescein-conjugated secondary
antibody and mounted with Vectashield mounting med-
ium with DAPI (Vector Laboratories, Burlington, CA,
USA). Slides were examined, photographed, and cells
counted under Olympus bright-field fluorescence micro-
scope. For quantification of BrdU-positive cells, 50 high-
power fields per sample was analyzed.
Concentration of cytokines and VEGF in supernatant
After experiments, cell culture medium was collected
a n ds t o r e da t- 8 0 ° Cp r i o rt oa n a l y s i s .C y t o k i n ea n d
VEGF concentrations in the supernatant were measured
using commercial ELISA kits according to the manufac-
turer’s recommendations (TNFa: Quantikine, R & D
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CINC-1>: Assay Designs, Ann Arbor, MI, cat. # 900-
0 7 4 ;I L - 1 0 :Q u a n t i k i n e ,R&DS y s t e m s ,M i n n e a p o l i s ,
MN, cat # R1000; VEGF: Quantikine, R & D systems,
Minneapolis, MN, cat. # RRV00). Optical density was
determined photometrically at 450 nm using the ELISA
plate reader, ELX800 (Bio-Tek
® Instruments, Winooski,
VT, USA). GRO/CINC-1 is a functional counterpart of
human IL-8 from rat and structural and functional
homology to human IL-8 [29]. ELISA kits had a mini-
mum detectable concentration of 5 pg/ml for TNFa,
7.75 pg/ml for IL-8, 4.91 pg/ml for IL-10, and 8.4 pg/ml
for VEGF. Cytokine levels were within the assay’s detec-
tion limits in all samples.
Real-time PCR (qRT-PCR)
Total RNA was extracted from E19 type II cells exposed
to 65%-hyperoxia for 24 h and 36 h or parallel normoxic
samples by a single-step method, and purified further
with the Rneasy Mini Kit (Invitrogen, Carlsbad, CA,
USA). Standard curves were generated for each primer
set and housekeeping gene 18S ribosomal RNA. Linear
regression revealed efficiencies between 96 and 99%.
Therefore, fold expressions of hyperoxic samples relative
to controls were calculated using the ΔΔCT method for
relative quantification (RQ). Samples were normalized to
the 18S rRNA. No differences in RQ values for 18S
were found between control and hyperoxic samples.
TaqMan primers were purchased from Assays-on-
Demand™ Gene Expression Products (Applied Biosys-
tems, Carlsbad, CA, USA). The following primers were
used: TNFa (cat. #: Rn99999017_m1), GRO/CINC-1
(rat equivalent of IL-8) (5’ primer:CATTAATATT-
TAACGATGTGGATGCG TTTCA;3’primer: GCCTAC-
C A T C T T T A A A C T G C A C A A T ) ,I L - 1 0( c a t .# :R n
99999012_m1), VEGF (cat. #: Rn00582935_m1) and 18S
(cat. #: Hs99999901_s1). Five micrograms of total RNA
were reverse-transcribed into cDNA by the Superscript
Double Stranded cDNA Synthesis kit (Invitrogen, Carls-
bad, CA, USA). To amplify the cDNA by qRT-PCR, 5 μl
of the resulting cDNA were added to a mixture of 25
μL of TaqMan Universal PCR Master Mix (Applied Bio-
systems, Carlsbad, CA, USA) and 2.5 μlo f2 0×A s s a y s -
on-Demand™ Gene Expression Assay Mix containing
forward and reverse primers and TaqMan-labeled probe
(Applied Biosystems, Carlsbad, CA, USA). Reactions
were performed in an ABI Prism 7000 Sequence Detec-
tion System (Applied Biosystems, Carlsbad, CA, USA).
All assays were performed in duplicate.
Statistical analysis
Results are expressed as mean ± SD from at least three
experiments, using different litters for each experiment.
For intergroup comparisons, data were analyzed with
unpaired Student’s t-test. A p-value < 0.05 was consid-
ered to be statistically significant.
Results
Effect of 65%-hyperoxia on fetal type II cell necrosis
Cell lysis analyzed by LDH-release into the supernatant
significantly increased 1.9-fold after 24 h of hyperoxia
(control = 19.8 ± 1.6 vs. hyperoxia = 37.0 ± 6.0; p <
0.05) and 2.6-fold after 36 h of hyperoxia (control =
20.7 ± 0.5 vs. hyperoxia = 54.5 ± 2.3; p <0 . 0 1 )w h e n
compared to controls (Figure 1A). We analyzed the
characteristic distribution of FATIICs at intervals of 6-
12 h during 65%-hyperoxia for 48 h with FACscan to
identify the characteristics of the double stained [AV-
positive and PI-positive] cells. As shown in Figure 1B,
the double stained cells increased gradually during 65%-
hyperoxia and peaked out at 36 h of hyperoxia, which
were significantly greater compared to the normoxic
cells (control = 0.39 ± 0.09 vs. hyperoxia = 1.08 ± 0.47;
p < 0.05) and then decreased rapidly (Figure 1B). How-
ever, the dual positive cells in normoxic cells increased
persistently after 36 h (Figure 1B). As shown in Figure
1B, selective AV-positive cells increased gradually during
65%-hyperoxia and peaked out at 24 h of hyperoxia,
which were significantly higher compared to the nor-
moxic cells (control = 0.40 ± 0.10 vs. hyperoxia = 1.51
± 0.43; p < 0.01) and then decreased rapidly (Figure 1B).
In contrast, selective PI-positive cells increased signifi-
cantly in a time-dependent manner during 65%-hyper-
oxia compared to the normoxic cells (Figure 1C).
According to these observations, the delayed increase at
36 h in the double positive cells may support the notion
that these cells might be late apoptotic or necrotic, as
they arose after the peak of early apoptotic cells; how-
ever, the percentage of the double positive cells were
less than 1.5% of the FATIICs exposed to 65%-hyper-
oxia. Based on these data, pure necrotic cells were
assessed by selective PI-positive cells with FACscan [30].
As shown in Figure 1D, 65%-hyperoxia increased the
modest increase in selective PI-stained cells after 24 h
and 36 h of hyperoixa (Figure 1D), and the percentage
of cellular necrosis, as measured by selective PI staining
[30], increased significantly after 24 h and 36 h of
hyperoxia when compared to the control cells (24 h-
control = 1.87 ± 0.45 vs. 24 h-hyperoxia = 5.74 ± 1.85;
p < 0.01; 36 h-control = 1.94 ± 0.48 vs. 36 h-hyperoxia
= 9.47 ± 3.17; p < 0.01) (Figure 1E).
Effect of 65%-hyperoxia on fetal type II cell apoptosis
DNA fragmentation assessed by TUNEL assay demon-
strated that 65%-hyperoxia increased the apoptosis
index 1.8-fold after 24 h (control = 1.9 ± 0.23 vs. hyper-
oxia = 3.4 ± 0.21; p < 0.05) and 1.9-fold after 36 h (con-
trol = 2.0 ± 0.12 vs. hyperoxia = 3.7 ± 0.06; p <0 . 0 1 )
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Figure 1 Effect of 65%-hyperoxia on fetal type II cell necrosis. (A) Graphical depiction showing LDH-release expressed as experimental
minus background LDH-release divided by maximum LDH-release in hyperoxic and normoxic cells. The results are represented as the mean ±
SD from 3 different experiments. (B) Graphical depiction showing the changes in the selective AV-positive cells and the dual positive (AV-
positive and PI-positive) cells during normoxia and 65%-hyperoxia for 48 h. The results are represented as the mean ± SD from 3 different
experiments. **; p < 0.01. (C) Graphical depiction showing the changes in the selective PI-positive cells during normoxia and 65%-hyperoxia for
48 h. The results are represented as the mean ± SD from 3 different experiments. **; p < 0.01. (D) Graphical depiction showing the distribution
of necrotic cells (PI-positive and AV-negative) under normoxic and hyperoxic conditions. (E) Graphical depiction showing cellular necrosis (PI-
positive and AV-negative) as a percentage of the total cell number in normoxic and hyperoxic cells. The results are represented as the mean ±
SD from 6 different experiments.
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centage of cells undergoing early apoptosis [selective
AV-positive cells] assessedb yF A C s c a nh a ds t a t i s t i c a l
increases in hyperoxic cells; however, the range was
within 1.9% (24 h-control = 0.40 ± 0.10 vs. 24 h-hyper-
oxia = 1.51 ± 0.43; p < 0.01; 36 h-control = 0.52 ± 0.11
vs. 36 h-hyperoxia = 0.86 ± 0.29; p <0 . 0 5 )( F i g u r e2 B ) .
Similarly, the percentage of late apoptotic or necrotic
cells (AV-positive and PI-positive cells) assessed by
FACscan increased statistically in hyperoxic cells; how-
ever the range was within 1.5% (24 h-control = 0.35 ±
0.09 vs. 24 h-hyperoxia = 0.57 ± 0.11; p < 0.01; 36 h-
control = 0.39 ± 0.09 vs. 36 h-hyperoxia = 1.08 ± 0.47;
p < 0.01) (Figure 2C). In addition, western blots for cas-
pase-3 showed that 65%-hyperoxia did not enhance level
of cleaved caspase-3 and concomitantly did not decrease
abundance of full-length procaspase-3 compared to con-
trol samples (Figure 2D).
Effect of 65%-hyperoxia on fetal type II cell proliferation
Cell proliferation was analyzed by DNA incorporation of
the thymidine analog 5-bromo-2’-deoxyuridine (BrdU).
65%-hyperoxia decreased type II cell proliferation by
36% after 24 h (control = 6.5 ± 0.25 vs. hyperoxia = 4.2
±0 . 2 0 ;p < 0.01) and by 56% after 36 h (control = 8.2 ±
0 . 3 5v s .h y p e r o x i a=3 . 8±0 . 2 0 ;p < 0.01) when com-
pared to controls (Figure 3A). Representative fluores-
cence immunocytochemistry fields from fetal lung type
II cells exposed to 65%-hyperoxia for 24 h and 36 h and
parallel normoxic cells are shown in Figure 3B.
Figure 2 Effect of 65%-hyperoxia on fetal type II cell apoptosis. (A) Graphical depiction showing detection and quantification of DNA
fragmentation analyzed by TUNEL assay in normoxic and hyperoxic cells. The results are represented as the mean ± SD from 3 different
experiments. (B) Graphical depiction showing early apoptotic cells (selective AV-positive cells) as a percentage of the total cell number in
normoxic and hyperoxic cells. The results are represented as the mean ± SD from 6 different experiments. (C) Graphical depiction showing late
apoptotic or necrotic cells (AV-positive and PI-positive cells) as a percentage of the total cell number in normoxic and hyperoxic cells. The results
are represented as the mean ± SD from 6 different experiments. (D) Western blot showing level of cleaved caspase-3 and abundance of full-
length of procaspase-3 during 65%-hyperoxia.
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from fetal type II cells
VEGF and cytokines released into the supernatant were
analyzed by ELISA. Results revealed that VEGF-release
decreased significantly by 18% after 24 h (control =
1394.6 ± 175.9 vs. hyperoxia = 1143 ± 97.4; p < 0.05) and
by 26% after 36 h of hyperoxia (control = 3105 ± 108.0
vs. hyperoxia = 2309 ± 178.1; p < 0.01) when compared
to controls (Figure 4A). As shown in Figure 4B, TNFa
levels were detected too low below 20 pg/ml in normoxic
and hyperoxic conditions, and TNFa-release decreased
significantly in hyperoxic samples compared to controls
(24 h-control = 17.3 ± 1.80 vs. 24 h-hyperoxia = 9.7 ±
0.53; p < 0.01; 36 h-control = 13.5 ± 1.05 vs. 36 h-hyper-
oxia = 10.6 ± 0.22; p < 0.05) (Figure 4B). 65%-hyperoxia
did not affect IL-1b or IL-6-release (data, not shown)
from FATIICs. However, IL-8 increased 1.3-fold after 24
h (control = 284 ± 9.0 vs. hyperoxia = 385 ± 5.5; p <
0.01) and 1.5-fold after 36 h of hyperoxia (control = 348
±2 3 . 6v s .h y p e r o x i a=5 1 3±6 8 . 5 ;p < 0.05) when com-
pared to controls (Figure 4C). In contrast, IL-10
decreased by 42% after 24 h (control = 100 ± 8.5 vs.
hyperoxia = 58 ± 3.1; p < 0.01) and by 70% after 36 h of
hyperoxia (control = 111 ± 10.5 vs. hyperoxia = 33 ± 7.4;
p < 0.01) compared to controls (Figure 4D).
Effect of 65%-hyperoxia on VEGF and cytokines gene
expression
As a result of analyzing VEGF and cytokine genes
expression using qRT-PCR, similar findings were
observed with ELISA findings. As shown in Figure 5A,
65%-hyperoxia resulted in a significant decrease in
VEGF mRNA by 18% and 64% after 24 h and 36 h,
respectively when compared to controls (24 h-control =
1.18 ± 0.10 vs. 24 h-hyperoxia = 0.86 ± 0.06; p <0 . 0 5 ;
36 h-control = 1.32 ± 0.12 vs. 36 h-hyperoxia = 0.48 ±
0.08; p < 0.01) (Figure 5A). And 65%-hyperoxia
increased IL-8 mRNA 3.6-fold after 24 h (control = 1.13
± 0.10 vs. hyperoxia = 4.03 ± 0.23; p < 0.01) and 9-fold
after 36 h (control = 1.21 ± 0.18 vs. hyperoxia = 10.80 ±
2.21; p < 0.05) (Figure 5B), whereas it decreased IL-10
mRNA by 24% after 24 h (control = 1.27 ± 0.04 vs.
hyperoxia = 0.97 ± 0.14; p < 0.05) and by 50% after 36 h
(control = 1.43 ± 0.11 vs. hyperoxia = 0.72 ± 0.06; p <
0.01) (Figure 5C) when compared to controls.
Effect of IL-10 preincubation of fetal type II cells before
exposure to 65%-hyperoxia
According to the former data showing that 65%-hyper-
oxia induces increased cell death and decreased VEGF-
release and cell proliferation and generates an imbalance
between the pro-inflammatory cytokine, IL-8 and the
anti-inflammatory cytokine, IL-10, in FATIICs. We eval-
uated whether preincubation of rIL-10 prior to hyper-
oxia would attenuate fetal type II cell injury secondary
to 65%-hyperoxia. E19 type II cells were preincubated
with 300 ng/ml of rat rIL-10 for 1 h prior to 65%-hyper-
oxia: 1) IL-10 administration decreases cell necrosis
and IL-8 release. As shown in Figure 6A, preincubation
of rIL-10 significantly reduced cellular necrosis (mea-
sured by LDH-release) by 17% after 24 h of hyperoxia
(untreated = 37.0 ± 5.99 vs. treated = 30.8 ± 3.56; p <
0.05) and by 27% after 36 h of hyperoxia (untreated =
54.5 ± 2.30 vs. treated = 39.8 ± 3.84; p < 0.01) respec-
tively, when compared to cells without rIL-10 (Figure
6A). FACS analysis findings were similar with LDH-
release, and showed cellular necrosis [PI-positive and
AV-negative] greatly decreased in treated cells when
Figure 3 Effect of 65%-hyperoxia on fetal type II cell proliferation. (A) Graphical depiction showing BrdU-positive cells in hyperoxic and
normoxic cells. The results are represented as the mean ± SD from 3 different experiments. (B) Representative fluorescence
immunocytochemistry fields of E19 type II cells exposed to 65%-hyperoxia for 24 h and 36 h and parallel control samples. BrdU positive cells are
labeled red. Nuclei were counterstained with DAPI (blue). Scale bar = 50 μm.
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tage of cellular necrosis [PI-positive and AV-negative]
significantly decreased in rIL-10-treated cells by 66%
after 24 h and 36 h of hyperoxia (24 h-untreated = 5.74
± 1.85 vs. 24 h-treated = 2.06 ± 0.39; p < 0.01; 36 h-
untreated = 9.47 ± 3.17 vs. 36 h-treated = 3.30 ± 0.56; p
< 0.01) (Figure 6C) when compared to untreated cells.
However, early apoptotic cells [AV-positive and PI-nega-
t i v ec e l l s ]m e a s u r e db yF A C S c a nw e r en o ta f f e c t e ds i g -
nificantly by rIL-10 (24 h-untreated = 1.51 ± 0.43 vs. 24
h-treated = 1.51 ± 0.47; 36 h-untreated = 0.86 ± 0.29 vs.
36 h-treated = 0.52 ± 0.44) (Figure 6D). In addition, the
dual positive cells (late apoptotic or necrotic cells) mea-
sured by FACscan was affected by rIL-10 only at 36 h of
hyperoxia (36 h-untreated = 1.08 ± 0.47 vs. 36 h-treated
= 0.49 ± 0.19; p < 0.01) (Figure 6E). Similarly, apoptosis
index assessed by TUNEL assay significantly decreased
by 22% after 36 h when compared to hyperoxic cells
w i t h o u tr I L - 1 0( 3 6h - u n t r e a t e d=3 . 7±0 . 0 6v s .3 6h -
treated = 2.9 ± 0.17; p < 0.01) (Figure 6F). As shown in
Figure 6G, IL-8-release significantly decreased by 22%
and 24% after 24 h and 36 h of hyperoxia respectively,
in treated cells compared to untreated cells (24 h-
untreated = 385 ± 5.5 vs. 24 h-treated = 302 ± 10.4; p <
0.01; 36 h-untreated = 513 ± 68.5 vs. 36 h-treated = 390
±1 8 . 5 ;p < 0.05) (Figure 6G). 2) IL-10 administration
increases cell proliferation and VEGF-release.A s
shown in Figure 7A, cell proliferation increased 1.3-fold
and 1.2-fold after 24 h and 36 h of hyperoxia, respec-
tively in treated cells compared to untreated cells (24 h-
untreated = 4.2 ± 0.20 vs. 24 h-treated = 5.4 ± 0.06; p <
0.01; 36 h-untreated = 4.5 ± 0.61 vs. 36 h-treated = 5.4
±0 . 7 2 ;p < 0.01) (Figure 7A). Similarly, VEGF-release
increased 1.2-fold after 24 h and 36 h of hyperoxia,
respectively in treated cells compared to untreated cells
(24 h-untreated = 1143 ± 97.4 vs. 24 h-treated = 1376 ±
206.6; p < 0.05; 36 h-untreated = 2309 ± 178.1 vs. 36 h-
treated = 2672 ± 102.0; p < 0.01) (Figure 7B).
Figure 4 Effect of 65%-hyperoxia on VEGF and cytokine release from fetal type II cells. Supernatants were processed to assess VEGF (A),
TNFa (B), IL-8 (C) and IL-10 (D) by ELISA in normoxic and hyperoxic cells. The results of IL-8, IL-10 and TNFa are represented as the mean ± SD
from 3 different experiments, and the results of VEGF are represented as the mean ± SD from 6 different experiments.
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The main findings of the present study are that 65%-
hyperoxia of cultured FATIICs increased cellular necro-
sis and IL-8 production, while decreased VEGF produc-
tion, cell proliferation and IL-10 production.
Interestingly, preincubation with rIL-10 before hyperoxia
protected FATIICs from injury secondary to 65%-hyper-
oxia by decreasing cellular necrosis and IL-8 production
and increasing VEGF production and cell proliferation.
In our investigations, we selected 65%-hyperoxia,
based on previous observation showing that 65%-hyper-
oxia exposure to newborn mice caused impairment of
lung architecture in adult mice [31]. Therefore, in the
current study, we investigated whether 65%-hyperoxia
induces any injurious effect to FATIICs that are key
components of the alveolar structure.
The present study showed that 65%-hyperoxia signifi-
cantly increased LDH-release when compared to control
samples. Exposure of hyperoxia causes direct oxidative
cell damage through increased production of reactive
oxygen species (ROS) [32]. Hence, lung damage second-
ary to hyperoxia is considered to be the direct results of
increased intracellular ROS, which is accompanied by a
secondary inflammatory response of the lungs [33]. All
these pathologic alterations converge toward a central
event, alveolar cell death [32].
Apoptosis, in the range of 0-3%, is a physiological
event during lung morphogenesis [34]. Our investiga-
tions demonstrated statistically significant increase of
TUNEL-positive fetal type II cells during 65%-hyperoxia
when compared to controls. However, the increased
levels of apoptosis measured by TUNEL assay ranged
between 3.4% and 3.7%, which were within the normal
physiological range. Similarly, early apoptotic cells mea-
sured by selective AV-positive staining [AV-positive and
PI-negative] ranged between only 1.0% and 1.9% during
Figure 5 Effect of 65%-hyperoxia on VEGF and cytokine genes expression. Graphical depiction showing that 65%-hyperoxia upregulates
VEGF (A) and IL-8 genes (B) and downregulates IL-10 (C) gene. The results of IL-8 and IL-10 are represented as the mean ± SD from 3 different
experiments, and the results of VEGF are represented as the mean ± SD from 6 different experiments.
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Figure 6 IL-10 decreases cell death and IL-8 in fetal type II cells exposed to 65%-hyperoxia. E19 cells were preincubated with a
concentration of 300 ng/ml of rat rIL-10 before exposing to 65%-hyperoxia for 24 h and 36 h. Samples were processed to assess cellular
necrosis, apoptosis and IL-8 released into the supernatant. (A) Graphical depiction showing LDH-release in treated and untreated cells. The
results are represented as the mean ± SD from 3 different experiments. (B) Graphical depiction showing distribution of cellular necrosis
measured by selective PI staining in treated and untreated cells. (C) Graphical depiction showing cellular necrosis (PI-positive and AV-negative
cells) expressed as a percentage of the total cell number in treated and untreated cells. The results are represented as the mean ± SD from 6
different experiments. (D) Graphical depiction showing early apoptotic cells (selective AV-positive cells) assessed by FACscan in treated and
untreated cells. The results are represented as the mean ± SD from 6 different experiments. (E) Graphical depiction showing late apoptotic or
necrotic cells (AV-positive and PI-positive cells) assessed by FACscan in treated and untreated cells. The results are represented as the mean ± SD
from 6 different experiments. (F) Graphical depiction showing DNA fragmentation assessed by TUNEL assay in treated and untreated cells. The
results are represented as the mean ± SD from 3 different experiments. (G) Graphical depiction showing IL-8 released into the supernatant in
treated and untreated cells. The results are represented as the mean ± SD from 3 different experiments.
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Page 10 of 1565%-hyperoxia. Our findings are somewhat similar to
previous investigation demonstrating 2.5% of apoptotic
cells in human fetal epithelial cells exposed to 95%-
hyperoxia, that revealed decreased compared to nor-
moxic cells [35].
However, there are some discrepancies between our
results and others’ regarding apoptotic activity in fetal
alveolar epithelial cells exposed to hyperoxia. Haaften’s
group demonstrated high apoptotic index assessed by
TUNEL assay, approximately 70%, in cultured rat type
II cells at E19.5 after exposure to 85%-hyperoxia for 36
h [36], and Huang’s group demonstrated 60% and 85%
of apoptotic index in cultured rat type II cells at E21
after 95%-hyperoxia for 24 h and 48 h, respectively [37].
These discrepancies may be due to different doses of
oxygen exposure and different experimental conditions.
Apoptotic activities show oxygen dose dependence pro-
portional to the amount of oxidants generated. Pre-
viously published data have shown lower concentrations
of H2O2 do not induce TUNEL-positive apoptosis, only
cell swelling, while intermediate doses of oxidants
induce mixed modes of cell death, some dying by apop-
tosis, some by cell swelling [38-40]. Currently, it has not
been clearly defined whether hyperoxia induces primar-
ily apoptotic or non-apoptotic death in vivo and in vitro.
However, previous reports have demonstrated that
epithelial cells generally show aspects of necrosis during
hyperoxia [1. 33, [41-45]]. These previous studies sup-
port our results in terms of fetal type II cell death
including necrosis and apoptosis analyzed by LDH-
release, TUNEL-assay and FACS analysis. In addition,
different experimental conditions, such as cell culture
plates used and the confluency of cells cultured may
partially explain some differences between our apoptotic
cells and those observed in other studies.
The current FACS’ findings regarding the characteris-
tics of FATIICs observed at intervals of 6-12 h during
65%-hyperoxia for 48 h showed that early apoptotic
cells declined remarkably after 24 h of hyperoxia,
whereas necrotic cells increased progressively in a time-
dependent manner, which implies apoptotic activities
m a yb es u p p r e s s e da st i m ep r o g r e s s e sd u r i n gt h ea c u t e
stage of sublethal hyperoxia while necrotic features are
accelerated. Considering our observations with respect
to fetal type II cell death, it may be speculated that cel-
lular necrosis may be more relevant than apoptotic cell
death in FATIICs during the initial stage of 65%-
hyperoxia.
In addition, our investigations demonstrated that
cleaved caspase-3 was not increased in FATIICs exposed
to 65%-hyperoxia compared to controls, which is a simi-
lar finding to previous investigation of human fetal lung
epithelial cells exposed to 95%-hyperoxia [35]. Current
observation regarding caspase-3 may suggest that, dur-
ing 65%-hyperoxia, caspases could prevent their own
activation resulting in apoptosis in FATIICs so it could
be possible that 65%-hyperoxia may trigger a caspase-
independent cell death pathway [46]. This speculation is
supported by our previous investigation showing that
non-caspase proteolytic enzyme is greatly enhanced pro-
portionally to the increase in fetal type II cell death dur-
ing hyperoxia [47].
Figure 7 IL-10 administration increases cell proliferation and VEGF-release in fetal type II cells exposed to 65%-hyperoxia. E19 cells
were preincubated with the concentration of 300 ng/ml of rat rIL-10 before exposing 65%-hyperoxia for 24 h and 36 h. Samples were
processed to assess cell proliferation and VEGF released into the supernatant. (A) Graphical depiction showing the percentage of cells
incorporating BrdU into nuclei in treated and untreated cells. The results are represented as the mean ± SD from 3 different experiments. (B)
Graphical depiction showing VEGF released into the supernatant in treated and untreated cells. The results are represented as the mean ± SD
from 6 different experiments.
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in 65%-oxygen demonstrated a decrease in cellular pro-
liferation. This result is congruent with others that
showed decreased cellular proliferation in FATIICs or
newborn lung epithelial cells exposed to hyperoxia
[37,48,49]. Current data on inhibition of type II cell pro-
liferation in 65%-hyperoxia might be explained by DNA
damage or cellular growth arrest [8]. Additionally, it is
notable that failure of type II cells to proliferate during
the 1st week of life may permanently alter postnatal
lung growth during a critical period of postnatal lung
development, which may play an important role in the
evolution of BPD in preterm infants [50].
Our present data on VEGF expression in FATIICs
showed significant decreases during 65%-hyperoxia for
36 h, which are consistent with data from premature
lung explants [35,51]. Epithelial-mesenchymal interac-
tions are considered to be necessary for lung vascular
development [52], and alveolar type II cells undergo
growth and differentiation in the presence of VEGF
[53]. Therefore, expression of VEGF from alveolar
epithelial cells is presumed to be responsible for alveolar
development [54]. In the current study, hyperoxia was
found to be capable of destroying FATIICs at the early
stage of hyperoxia, which may contribute to the genesis
of lung injury in preterm lungs. Although VEGF is
known to act as a prototypic growth factor for endothe-
lial and epithelial cells [53], growth factors may have the
dual effect of either being protective or harmful; there-
fore, the growth factor including VEGF may be harmful
if overexpressed. This lends support to the finding that
VEGF decreases in bronchoalveolar lavage fluid (BALF)
until 3 days from birth in premature newborns with
respiratory distress syndrome, whereas it increases
greatly (2.2-fold) in BALF of 1-week-old preterm new-
borns who had BPD compared to the levels observed at
3 days of life. In contrast, in premature newborns with-
out BPD, VEGF at 1 week of age does not increase
greatly (1.1-fold) compared to the levels observed at 3
days of age [55]. This increase in VEGF in preterm new-
borns with BPD is presumed to be caused by the
increased production of VEGF possibly due to inflam-
matory cells, which may be the source of VEGF. More-
over, the excessive VEGF can act as a potent
permeability factor. In addition, the location of the
VEGF expression appears to be important according to
previous observations which showed that increases in
plasma VEGF were related to higher mortality [56],
while increases in the levels of VEGF in the epithelial
lining fluid were associated with the recovery of patients
with acute respiratory distress syndrome [57]. Based on
the previously reported evidence, the increase in VEGF
in FATIICs preincubated with rIL-10 can be assumed to
contribute to the protection of type II cells. This is also
supported by previously published reports which
demonstrated that VEGF production has a protective
effect against hyperoxic acute lung injury [58].
Our investigation of cytokines showed very low levels
of TNFa (< 20 pg/ml) in both normoxic and hyperoxic
conditions, implying that the role of TNFa is not clear
in hyperoxic injury, and cytokine release may not be
TNFa-mediated in FATIICs during hyperoxia. Our
speculation is supported by previous evidence showing
that the blocking of TNFa function is not effective in
reducing lung injury during hyperoxia [59]. In addition,
our results of low levels of TNFa may explain partly
why caspase 3 did not increase in FATIICs exposed to
65%-hyperoxia, based on previous evidence showing that
inhibition of TNFa prevents hyperoxia-mediated activa-
tion of caspase 3 in type II cells [60]. However, hyper-
oxia affected IL-8 and IL-10-release in FATIICs. Our
investigations showed that under normoxic conditions,
IL-8 concentrations increased and IL-10 concentrations
were nearly static overtime (see control samples at 24 h
and 36 h in Figure 4C & Figure 4D); in contrast, under
hyperoxic conditions, IL-8 increased significantly in a
time-dependent manner, while IL-10 significantly
decreased. Considering all of these responses, it may be
suggested that under normoxic conditions, IL-10 may
have a counterregulatory effect to inhibit inflammation,
whereas under hyperoxic conditions, IL-10 failed to
optimize its protective effect. Hence, it is more suspi-
cious that balance between pro- and anti-inflammatory
cytokines is shifted by a combination of an increase of
pro-inflammatory cytokine and a stronger decrease of
an anti-inflammatory cytokine rather than by increase in
pro-inflammatory cytokines.
Our observations of IL-8 upregulation are consistent
with previous observations showing that IL-8 was upre-
gulated by oxygen tension in adult type II cells, which
was independent of IL-1 receptor pathway [61], and IL-
8 increased in adult human airway epithelial cells
exposed to hyperoxia [62].
Our observation that preincubation with rIL-10 atte-
nuated cellular necrosis and IL-8-release, and promoted
cell proliferation and VEGF-release in FATIICs exposed
to 65%-hyperoxia is both important and novel. Mechan-
isms by which IL-10 reduces type II cell injury second-
ary to hyperoxia are not clearly defined yet. However,
some plausible explanations can be considered. First, IL-
10 could directly affect IL-8 production by inhibiting
the activation of NF-kB, a pivotal transcription factor
modulating inflammation. Also the inhibitory effect of
IL-10 on NF-kB could induce increases in cell prolifera-
tion by allowing entry to the S-1 phase. Second, IL-10
could indirectly influence IL-8 production through its
effect on modulating IL-8 receptors. The effect of IL-10
on suppressing receptors of pro-inflammatory cytokines
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IL-8 receptors are involved in one of the pathways for
genesis of intracellular oxygen radical species by binding
to the tyrosine kinase receptors including PDGF (plate-
let-derived-growth-factor) and EGF (epidermal growth
factor) located on the surface of type II cells [64].
Therefore, suppression of IL-8 receptors by IL-10 may
contribute to the prevention of additional type II cell
death. Third, the effect of IL-10 in reducing type II cell
necrosis could be attributed to inhibition of proteolytic
enzymes, which might contribute to increased VEGF
production. Although our in-vivo experimental study
suggests that IL-10 is a possible therapeutic option to
target acute lung injury in preterm lungs, exploration of
the optimal time and dose of IL-10 is required given on
the previous observation that increased systemic inflam-
mation and a worse outcome can result from higher
doses of adenoviruses [65].
Conclusions
This is the first experimental in-vivo study investigating
two kinds of fetal type II cell injury, cell death and
inflammatory response, which are both inducible during
hyperoxia, and whether rIL-10 may be effective in
attenuating two mechanisms of fetal type II cell injury
secondary to hyperoxia.
In summary, our investigation suggests that 65%-
hyperoxia of FATIICs induces increased cellular necro-
sis, decreased cell proliferation and VEGF production,
and generates an imbalance between pro- and anti-
inflammatory cytokines, and addition of rIL-10 reduces
cellular necrosis and IL-8 production and promotes
cell proliferation and VEGF production in FATIICs.
Our in vivo studies imply that IL-10 might be a pro-
mising therapeutic agent for attenuating or even pre-
venting acute lung injury secondary to hyperoxia in
premature lungs.
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